Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Yoshito Komatsu

Hokkaido University Hospital

Japan

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

100%

Internal Medicine

20%

Oncology

90%

Cancer Therapy

50%

Targeted Therapy

40%

Tumor Suppression

40%

Neoadjuvant Therapy

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)

Article Link

Year:

2025

Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment

Article Link

Year:

2025

Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial

Article Link

Year:

2025

Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors

Article Link

Year:

2025

Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer

Article Link

Year:

2024

Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer

Article Link

Year:

2024

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial

Article Link

Year:

2024

Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B

Article Link

Year:

2024

A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801

Article Link

Year:

2024

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial

Article Link

Year:

2024

Correlation of <i>UGT1A1</i> Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)

Article Link

Year:

2023

Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers

Article Link

Year:

2023

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Article Link

Year:

2023

Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis

Article Link

Year:

2023

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer

Article Link

Year:

2022

Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study

Article Link

Year:

2022

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Article Link

Year:

2021

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

Article Link

Year:

2021

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

Article Link

Year:

2021

Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)

Article Link

Year:

2020

Collaborators9

Shunsuke Kondo

Professor

Tokyo Women's Medical University

JAPAN

Taroh Satoh

Osaka University Hospital

JAPAN

Tadamichi Denda

Head

Kanagawa Cancer Center

JAPAN

Yasuyoshi Sato

University of Tokyo

JAPAN

Yosuke Togashi

Okayama University

JAPAN

Hiroshi Kawachi

Cancer Institute Hospital of Japanese Foundation for Cancer Research

JAPAN

Shogo Nomura

Project Lecturer

University of Tokyo

JAPAN

Satoshi Yuki

Hokkaido University Hospital

JAPAN

Hiromichi Ebi

Division Chief

Aichi Cancer Center

JAPAN

How do I reach out?

Meet Kite AI